2. NF-κB
  3. IKK
  4. IMD-0560

IMD-0560 is a novel IκB kinase β inhibitor.

For research use only. We do not sell to patients.

IMD-0560 Chemical Structure

IMD-0560 Chemical Structure

CAS No. : 439144-66-8

Size Price Stock Quantity
Solution
10 mM * 1 mL in Ethanol USD 198 In-stock
Solid
5 mg USD 180 In-stock
10 mg USD 288 In-stock
25 mg USD 518 In-stock
50 mg USD 778 In-stock
100 mg USD 1090 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

IMD-0560 Related Antibodies

Top Publications Citing Use of Products

View All IKK Isoform Specific Products:

View All Isoforms
IKK-α IKK-β IKK IKKε TBK1

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

IMD-0560 is a novel IκB kinase β inhibitor.

IC50 & Target[1]

IKKβ

 

In Vitro

Pretreatment with IMD-0560 inhibits both IκBα degradation and p65 phosphorylation induced by TNFα. IMD-0560 also suppresses TNFα-induced transcriptional activity. Pretreatment with IMD-0560 strongly inhibits TNFα-induced cell invasion. Pretreatment with IMD-0560 suppresses MMP-9 activity by inhibiting MMP-9 expression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IMD-0560 Related Antibodies
In Vivo

The tumor size is reduced in the IMD-0560-treated groups in a dose-dependent manner, and no tumor is detected in some mice treated with 5 mg/kg IMD-0560. Zygoma destruction is significantly suppressed in the IMD-0560-treated groups compare to the control groups. Although the tumor size in the 5 mg/kg IMD-0560-treated group is smaller than that of the 3 mg/kg IMD-0560-treated group, the inhibitory effect of each treatment on zygoma destruction is similar[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

428.12

Formula

C15H8BrF6NO2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=C(C=CC(Br)=C1)O)NC2=C(C=CC(C(F)(F)F)=C2)C(F)(F)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

Ethanol : 50 mg/mL (116.79 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3358 mL 11.6790 mL 23.3579 mL
5 mM 0.4672 mL 2.3358 mL 4.6716 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% EtOH    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.84 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% EtOH    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.84 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References
Cell Assay
[1]

Cell migration is assessed in a modified chamber containing a gelatin-coated porous membrane. IMD-0560 is placed in the upper chamber 2 hrs prior to TNFα treatment, and TNFα is placed in the lower chamber at 10 ng/mL; then, the chamber is incubated for 24 hrs. Next, the cells attached to the upper surface of the membrane are scraped off, and the cells that migrate to the lower surface are fixed and stained with DAPI[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1]

Sixty male mice, weighing approximately 20 g at 8 to 10 weeks of age are used. They are anesthetized using ether, and 0.1 mL of SCCVII in DMEM is injected into the left masseter region. The mice are randomly separated into six groups with similar average body weights. One week (early treatment: E) or 2 weeks (late treatment: L) after injection, the mice are injected between the left masseter region and the surface of the left mandibular bone with vehicle (50 μL of carboxymethyl-cellulose: CMC/mouse, n=10) or IMD-0560 (3 or 5 mg/kg/50 μL of CMC/mouse, n=10), 3 times per week for a total of 3 weeks (E) or 2 weeks (L). The tumor sizes are assessed using calipers, and the tumor volume is calculated. At the end of week 3, all surviving mice are euthanized, and the heads of the mice are fixed in 3.7% formaldehyde[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
Ethanol 1 mM 2.3358 mL 11.6790 mL 23.3579 mL 58.3948 mL
5 mM 0.4672 mL 2.3358 mL 4.6716 mL 11.6790 mL
10 mM 0.2336 mL 1.1679 mL 2.3358 mL 5.8395 mL
15 mM 0.1557 mL 0.7786 mL 1.5572 mL 3.8930 mL
20 mM 0.1168 mL 0.5839 mL 1.1679 mL 2.9197 mL
25 mM 0.0934 mL 0.4672 mL 0.9343 mL 2.3358 mL
30 mM 0.0779 mL 0.3893 mL 0.7786 mL 1.9465 mL
40 mM 0.0584 mL 0.2920 mL 0.5839 mL 1.4599 mL
50 mM 0.0467 mL 0.2336 mL 0.4672 mL 1.1679 mL
60 mM 0.0389 mL 0.1946 mL 0.3893 mL 0.9732 mL
80 mM 0.0292 mL 0.1460 mL 0.2920 mL 0.7299 mL
100 mM 0.0234 mL 0.1168 mL 0.2336 mL 0.5839 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IMD-0560 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IMD-0560439144-66-8IMD0560IMD 0560IKKIκB kinaseI kappa B kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IMD-0560
Cat. No.:
HY-105661
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.